Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 3,334 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Andrew Hollman Meyer also recently made the following trade(s):

• On Monday, February 3rd, Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86.
• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total transaction of $731,769.92.

Janux Therapeutics Price Performance

JANX stock opened at $31.50 on Thursday. Janux Therapeutics, Inc. has a 1 year low of $29.63 and a 1 year high of $71.71. The company has a market cap of $1.65 billion, a P/E ratio of -26.92 and a beta of 3.16. The firm has a 50-day moving average of $42.23 and a 200 day moving average of $47.67.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Janux Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of JANX. Mirae Asset Global Investments Co. Ltd. grew its holdings in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Janux Therapeutics by 639.5% during the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company’s stock valued at $924,000 after buying an additional 17,592 shares during the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Janux Therapeutics during the third quarter valued at approximately $239,000. Victory Capital Management Inc. grew its holdings in shares of Janux Therapeutics by 143.4% during the third quarter. Victory Capital Management Inc. now owns 29,745 shares of the company’s stock valued at $1,351,000 after buying an additional 17,525 shares during the last quarter. Finally, Plato Investment Management Ltd grew its holdings in shares of Janux Therapeutics by 18.7% during the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, November 22nd. William Blair reiterated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partners upped their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Lifesci Capital upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.00.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.